This inventor holds 1 USPTO granted patent. Top assignee: C4 Therapeutics, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Meiqi Li
Introduction
Meiqi Li is an accomplished inventor based in Watertown, MA (US). He has made significant strides in the field of targeted protein degradation, particularly concerning the BRD9 protein. His work is crucial for developing treatments for disorders mediated by BRD9, including abnormal cellular proliferation.
Latest Patents
Meiqi Li holds a patent for "Selected compounds for targeted degradation of BRD9." This patent includes selected BRD9 protein degradation compounds and morphic forms thereof, which are essential for addressing various medical conditions.
Career Highlights
Li is currently employed at C4 Therapeutics, Inc., where he continues to push the boundaries of innovation in drug development. His expertise in targeted degradation has positioned him as a key player in the biotechnology sector.
Collaborations
Meiqi Li collaborates with talented professionals, including Katrina L. Jackson and Christopher G. Nasveschuk. These partnerships enhance the research and development efforts at C4 Therapeutics, Inc.
Conclusion
Meiqi Li's contributions to the field of biotechnology and his innovative patent for BRD9 degradation compounds highlight his role as a leading inventor. His work promises to advance treatment options for various disorders, showcasing the impact of targeted protein degradation in modern medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile